Tags

Type your tag names separated by a space and hit enter

Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease.
J Alzheimers Dis 2015; 47(4):1009-19JA

Abstract

BACKGROUND

In a previous trial, treatment with soy isoflavones was associated with improved nonverbal memory, construction abilities, verbal fluency, and speeded dexterity compared to treatment with placebo in cognitively healthy older adults.

OBJECTIVE

The current trial aimed to examine the potential cognitive benefits of soy isoflavones in patients with Alzheimer's disease.

METHODS

Sixty-five men and women over the age of 60 were treated with 100 mg/day soy isoflavones, or matching placebo capsules for six months. APOE genotype was determined for all participants. Cognitive outcomes and plasma isoflavone levels were measured at baseline, and at two additional time points: three and six months after baseline.

RESULTS

Of the sixty-five participants enrolled, thirty-four (52.3%) were women, and 31 (47.7%) were APOEɛ4 positive. Average age was 76.3 (SD = 7.2) years. Fifty-nine (90.8%) subjects completed all study visits. Plasma isoflavone levels increased in subjects treated with soy isoflavones compared to baseline and to placebo, although intersubject variability in plasma levels was large. No significant differences in treatment effects for cognition emerged between treatment groups or genders. Exploratory analyses of associations between changes in cognition and plasma isoflavone levels revealed an association between equol levels, and speeded dexterity and verbal fluency.

CONCLUSIONS

Six months of 100 mg/day treatment with soy isoflavones did not benefit cognition in older men and women with Alzheimer's disease. However, our results suggest the need to examine the role of isoflavone metabolism, i.e., the ability to effectively metabolize soy isoflavones by converting daidzen to equol when attempting to fully clarify the cognitive effects of isoflavones.

Authors+Show Affiliations

Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA. Geriatric Research, Education, and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA. Geriatric Research, Education, and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA. Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, WI, USA.Division of Pathology and Laboratory Medicine, Department of Pediatrics University of Cincinnati, Cincinnati, OH, USA.Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA. Geriatric Research, Education, and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA. Geriatric Research, Education, and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA. Geriatric Research, Education, and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

26401779

Citation

Gleason, Carey E., et al. "Cognitive Effects of Soy Isoflavones in Patients With Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 47, no. 4, 2015, pp. 1009-19.
Gleason CE, Fischer BL, Dowling NM, et al. Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease. J Alzheimers Dis. 2015;47(4):1009-19.
Gleason, C. E., Fischer, B. L., Dowling, N. M., Setchell, K. D., Atwood, C. S., Carlsson, C. M., & Asthana, S. (2015). Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease : JAD, 47(4), pp. 1009-19. doi:10.3233/JAD-142958.
Gleason CE, et al. Cognitive Effects of Soy Isoflavones in Patients With Alzheimer's Disease. J Alzheimers Dis. 2015;47(4):1009-19. PubMed PMID: 26401779.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease. AU - Gleason,Carey E, AU - Fischer,Barbara L, AU - Dowling,N Maritza, AU - Setchell,Kenneth D R, AU - Atwood,Craig S, AU - Carlsson,Cynthia M, AU - Asthana,Sanjay, PY - 2015/9/25/entrez PY - 2015/9/25/pubmed PY - 2016/7/7/medline KW - Alzheimer’s disease KW - clinical trial KW - cognition KW - daidzein KW - equol KW - genistein KW - phytoestrogens KW - soy isoflavones SP - 1009 EP - 19 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 47 IS - 4 N2 - BACKGROUND: In a previous trial, treatment with soy isoflavones was associated with improved nonverbal memory, construction abilities, verbal fluency, and speeded dexterity compared to treatment with placebo in cognitively healthy older adults. OBJECTIVE: The current trial aimed to examine the potential cognitive benefits of soy isoflavones in patients with Alzheimer's disease. METHODS: Sixty-five men and women over the age of 60 were treated with 100 mg/day soy isoflavones, or matching placebo capsules for six months. APOE genotype was determined for all participants. Cognitive outcomes and plasma isoflavone levels were measured at baseline, and at two additional time points: three and six months after baseline. RESULTS: Of the sixty-five participants enrolled, thirty-four (52.3%) were women, and 31 (47.7%) were APOEɛ4 positive. Average age was 76.3 (SD = 7.2) years. Fifty-nine (90.8%) subjects completed all study visits. Plasma isoflavone levels increased in subjects treated with soy isoflavones compared to baseline and to placebo, although intersubject variability in plasma levels was large. No significant differences in treatment effects for cognition emerged between treatment groups or genders. Exploratory analyses of associations between changes in cognition and plasma isoflavone levels revealed an association between equol levels, and speeded dexterity and verbal fluency. CONCLUSIONS: Six months of 100 mg/day treatment with soy isoflavones did not benefit cognition in older men and women with Alzheimer's disease. However, our results suggest the need to examine the role of isoflavone metabolism, i.e., the ability to effectively metabolize soy isoflavones by converting daidzen to equol when attempting to fully clarify the cognitive effects of isoflavones. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/26401779/Cognitive_Effects_of_Soy_Isoflavones_in_Patients_with_Alzheimer's_Disease_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-142958 DB - PRIME DP - Unbound Medicine ER -